SiSaf is a UK-headquartered biotech startup that develops drugs using Bio-Courier technology. The company focuses on drug development leveraging its Bio-Courier platform. It has raised $13.2 million in a Series B round. The Series B was led by Singapore-based Vickers Venture Partners. The funding details were reported via an announcement; no additional financial terms or participants were specified in the article. SiSaf is a UK-headquartered commercial-stage biopharmaceutical company pioneering ProSilic, a patented bio-courier technology that combines porous silicon and liposomes. ProSilic is designed to improve stability, solubility, bioavailability, release and routes of administration for a wide range of molecules. The company has a dermatology-focused pipeline and also operates subsidiaries in cosmetic skincare and nutraceuticals. SiSaf says it does not discover new drugs but formulates existing ones to enhance efficacy and reduce limitations such as poor solubility or stability. The company recently showcased ProSilic at the South Beach Symposium and plans to use new funding to accelerate development of its dermatology programs. No revenue or user metrics are disclosed in the article. SiSaf develops next-generation silicon nanotechnology for drug delivery. The company is described in the article as a silicon nanotechnology drug delivery specialist. The fundraise was reported from Singapore. Vickers Venture Partners, a VC firm with a global footprint, led the financing. Exen Capital participated in the round, and Invest Northern Ireland, an earlier investor, followed on. No operating metrics or uses of proceeds were disclosed in the article.

Total raised

$21M

Funding rounds

3

Latest round

Series B

Latest activity

Nov 2020